Cayman Sd-06, 1-[4-[5-(4-Chlorophenyl)-4-(4-Pyrimidinyl)-1h-Pyraz

SD-06 is an ATP-competitive inhibitor of p38α MAPK (IC₅₀ = 0.016 µM).¹ It is selective for p38α over p38β, p38γ, and p38δ MAPKs (IC₅₀s = 0.677, >100, and >100 µM, respectively), as well as a panel of 54 additional kinases (IC₅₀s = >3 µM for all). SD-06 inhibits LPS-induced TNF-α, IL-6, and IL-1β release from primary human monocytes (IC₅₀s = 79.4, 106.9, and 105.9 nM, respectively). It decreases IL-1β-induced production of prostaglandin E₂ (PGE₂; Item No. 14010) in patient-derived rheumatoid arthritis synovial fibroblasts (RASFs; IC₅₀ = 96.2 nM). SD-06 (30 mg/kg) reduces carrageenan-induced paw swelling and hyperalgesia in rats. It also reduces the incidence of arthritis in a mouse model of collagen-induced arthritis and protects against joint and bone destruction in a rat model of streptococcal cell wall-induced arthritis.

WARNING This product is not for human or veterinary use.